2,418 Shares of Amgen Inc. $AMGN Bought by IRON Financial LLC

Amgen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • IRON Financial LLC acquired 2,418 Amgen shares worth approximately $1.02 million during the third quarter. Institutional investors collectively own 76.5% of Amgen’s outstanding stock.
  • Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $389.71. Recent targets ranged from $230 to $457.
  • Amgen exceeded quarterly expectations, reporting $6.29 in EPS and $10.05 billion in revenue, while maintaining a quarterly dividend of $2.52 per share, or $10.08 annually.
  • Interested in Amgen? Here are five stocks we like better.

IRON Financial LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,418 shares of the medical research company's stock, valued at approximately $1,019,000.

Other hedge funds have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $1,831,903,000. Wellington Management Group LLP boosted its position in shares of Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock worth $993,031,000 after acquiring an additional 2,514,254 shares in the last quarter. BlackRock Inc. boosted its position in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Amgen by 702.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock valued at $647,126,000 after acquiring an additional 1,344,010 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Robert W. Baird boosted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an "underperform" rating in a research report on Wednesday, August 5th. Barclays raised their target price on Amgen from $380.00 to $400.00 and gave the company an "equal weight" rating in a report on Wednesday. Truist Financial lifted their price target on Amgen from $362.00 to $380.00 and gave the company a "hold" rating in a research note on Wednesday, October 7th. HSBC downgraded Amgen from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $445.00 to $425.00 in a research report on Thursday, September 10th. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Amgen in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $389.71.

Check Out Our Latest Report on Amgen

Insider Activity at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

  • Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
  • Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
  • Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
  • Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Amgen Price Performance

Shares of AMGN opened at $439.26 on Monday. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $450.98. The business has a 50-day simple moving average of $417.70 and a two-hundred day simple moving average of $378.08. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock has a market cap of $237.48 billion, a PE ratio of 27.30, a PEG ratio of 3.21 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period last year, the company earned $6.02 earnings per share. The business's quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts anticipate that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen's dividend payout ratio (DPR) is 62.65%.

Amgen Company Profile

(Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines